Implications Stemming From FDA Requirement for Extremely Large Cardiovascular Outcomes Study for Orexigen's Contrave (VVUS, $8.00)Sunday, June 5, 2011 · 3:44 pm |
|
For Yearly-Access Subscribers OnlyFriday, January 1, 1999 · 4:00 am |
|
For Monthly-Access Subscribers OnlyFriday, January 1, 1999 · 3:00 am |
|
There are 3 reports on file. |